To learn more about Korea’s drug registration process, please click here.

In recent years, Korea has seen significant growth in its pharmaceutical sector. A combination of improving economic indicators and a growing drug market make this nation an attractive market for international companies. Given its highly developed healthcare system and growing aging population, the demand for new and effective medications is high. This presents expansive opportunities for foreign companies aiming for drug approval in the country.

The Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food and Drug Administration (KFDA) until 2013, is the pivotal regulatory body that oversees the safety and efficacy of drugs in the country. It is the MFDS’s responsibility to ensure compliance with international and domestic standards, making it a central figure in the Korea drug registration process.

Overview of the Drug Registration Pathway in Korea

Entering a new market requires understanding and navigating its specific regulatory landscape.

Required Documentation

For pharmaceutical registration in Korea, companies must submit a comprehensive dossier of documents, which is crucial for the Ministry of Food and Drug Safety (MFDS) to evaluate the drug’s safety, efficacy, and quality. This dossier typically includes detailed information about the drug’s composition, manufacturing process, clinical trial data, and proposed labeling. The documentation should follow the Common Technical Document (CTD) format, a standardized structure that facilitates regulatory review and ensures that all necessary information is presented clearly and comprehensively.

Companies should meticulously prepare this documentation to avoid delays in the approval process. The dossier must be thorough and precise, reflecting the latest research and development findings to prevent any discrepancies that could raise concerns during the review. Translation of some documents into Korean will be necessary, and adherence to local regulatory standards is critical (Food and Drug Safety Ministry). Ensuring that all documents are current and accurate is vital, as outdated or inconsistent information can significantly impede the approval process.

Engaging a local regulatory consultant with expertise in Korean regulations and language capabilities can be extremely beneficial in preparing this critical documentation. Local experts can help navigate the complex regulatory environment and ensure compliance with all requirements. Any errors or omissions in the dossier can lead to extended review timelines, additional costs, and, in the worst-case scenario, rejection of the application. Therefore, investing in proper documentation and local expertise is essential for a smooth and successful drug registration process in Korea.

Clinical Trial Data Requirements

Clinical trials are foundational in the process of drug registration in Korea. Foreign companies must provide comprehensive evidence of a drug’s safety and efficacy through clinical trial data, which typically includes results from Phase I to Phase III trials. These trials must be rigorously designed and conducted according to both Korean and international standards, ensuring that the data collected is robust and scientifically sound. The data must demonstrate that the drug is safe for use and effective for its intended purpose, meeting the stringent criteria set by the Ministry of Food and Drug Safety (MFDS).

The MFDS conducts a meticulous review of the submitted clinical trial data, and any discrepancies or inadequacies can lead to significant delays in the approval process (Food and Drug Safety Ministry). Therefore, it is essential for companies to ensure that the data is not only robust and consistent but also transparent. Detailed documentation of trial protocols, methodologies, and results is crucial. Companies should be prepared for potential requests from the MFDS for additional analyses or clarifications, which can arise if the submitted data raises any questions or if further information is needed to verify the drug’s safety and efficacy.

Collaborating with local clinical research organizations (CROs) or consultants who have a deep understanding of MFDS expectations and the Korean clinical trial environment can prove invaluable. These local experts can provide critical insights into the nuances of conducting clinical trials in Korea, ensuring that the trials are designed and executed in a manner that aligns with regulatory requirements. This collaboration can help mitigate risks, streamline the submission process, and enhance the likelihood of a successful drug registration by ensuring that the clinical trial data meets all necessary standards and expectations set by the MFDS.

Regulatory Timelines

Achieving drug approval in Korea is a time-sensitive process that requires careful planning and coordination. From the initial submission of documents to final approval, companies should anticipate a timeline of approximately 18 to 24 months (Food and Drug Safety Ministry). This period can vary based on the complexity of the drug, the completeness of the submission, and the efficiency with which the applicant responds to requests from the Ministry of Food and Drug Safety (MFDS). Timely and accurate submission of all required documents is crucial, as any delays or errors can extend the timeline significantly.

The regulatory review process in Korea involves multiple stages, each critical to the approval of new drugs. Companies must navigate these stages carefully and maintain proactive engagement with the Ministry of Food and Drug Safety (MFDS) to ensure a smooth and efficient review process. Open communication with the MFDS is essential to promptly address any queries or issues that may arise.

The key stages of the regulatory review process include:

Preliminary Review: Initial assessment of the submitted documents to ensure completeness and compliance with regulatory requirements.
Main Review: In-depth evaluation of the drug’s safety, efficacy, and quality based on the submitted data, including clinical trial results.
Final Approval: Final decision-making stage where the MFDS grants or denies approval based on the findings from the main review.

During these stages, the MFDS may request additional information or clarification. Companies should maintain open channels of communication with the MFDS to address any queries or issues promptly.

Monitoring the progress of the application regularly and being prepared to adjust strategies based on interim feedback is also important (Food and Drug Safety Ministry). Engaging a local regulatory affairs specialist who understands the intricate details of the Korean regulatory landscape can be highly beneficial. These specialists can provide valuable insights and guidance, helping to navigate the regulatory timelines more effectively. By ensuring that all deadlines are met and that the process moves as swiftly as possible, companies can increase their chances of achieving timely drug approval in Korea.

Special Considerations for International Companies

Entering a new market is never solely a matter of fulfilling regulatory requirements. There are cultural and regulatory specifics that foreign companies need to account for.

Cultural Nuances

Understanding and navigating Korean business culture is vital for international companies engaging in pharmaceutical registration in the country. Respect for hierarchy is paramount in Korean society; age and position are highly regarded, and decisions are typically made from the top down. This hierarchical structure means that younger or lower-ranking employees may defer to their seniors, and it is crucial for foreign companies to recognize and respect this dynamic in all interactions. Demonstrating respect for hierarchy by addressing senior executives first and acknowledging their status can facilitate smoother business engagements.

Relationship-building, or ‘jeong,’ is another significant aspect of Korean business culture. ‘Jeong’ represents a deep and emotional bond between people, which extends beyond mere professional interactions and encompasses genuine personal connections. Politeness, modesty, and humility are highly valued in Korean society, and these qualities should be reflected in all business dealings. International companies should strive to build authentic relationships with their Korean counterparts, understanding that trust and mutual respect are foundational to successful long-term partnerships.

Fostering good relationships with Korean counterparts involves understanding local social intricacies, such as using appropriate honorifics and adhering to gift-giving etiquette. Honorifics are a crucial part of the Korean language, and using them correctly shows respect for the individual’s status and age. Gift-giving is another important tradition in Korean business culture, often seen as a gesture of goodwill and appreciation. By respecting these cultural nuances, international companies can build strong, trusting relationships with their Korean partners, which can significantly enhance their ability to navigate the pharmaceutical registration process successfully.

Foreign companies may encounter regulations that are unique to Korea. It is essential to have an expert who understands the ins and outs of Korea pharmaceutical registration. They can guide the process smoothly, help with language barriers, and interpret complex regulations.

Streamlining the Registration Process for International Entrants

Korea’s regulatory landscape can be challenging, but strategies exist that can significantly streamline the process.

Collaborating with Local Partners

Partnering with a local entity, such as a Korean pharmaceutical company, can be an effective strategy for foreign enterprises navigating the drug registration process in Korea. Local partners typically have established relationships with regulatory authorities and possess an in-depth understanding of the nuances involved in Korean pharmaceutical regulations. This existing network can be instrumental in facilitating smoother communication and expediting the approval process, as local partners can provide valuable insights and leverage their connections to address any regulatory issues promptly.

These partnerships also enable foreign companies to better understand the Korean market landscape, including potential risks and opportunities. A local partner can assist in identifying market entry strategies that are both culturally and commercially viable, ensuring that the foreign company’s approach is well-aligned with local business practices and consumer preferences. By collaborating with a local entity, foreign companies can navigate the complexities of local regulations more effectively, from ensuring compliance with specific documentation requirements to understanding and adapting to local customs and business etiquette. This strategic collaboration not only enhances the likelihood of successful drug registration but also positions the foreign company for long-term success in the Korean market.

Leveraging Global Harmonization Initiatives

Korea’s participation in the International Council for Harmonisation (ICH) influences the standardization of global regulatory requirements. Engaging in ICH initiatives can be a strategic move for pharmaceutical companies seeking drug approval in Korea, as it may streamline the registration process by aligning it with international standards. By adhering to ICH guidelines, companies can ensure that their drug development and documentation practices are consistent with those accepted globally, which simplifies the regulatory review process in multiple markets.

Aligning with ICH standards indicates a level of credibility and reliability, facilitating faster and more efficient review and approval processes by the MFDS. This global harmonization reduces the need for redundant testing and minimizes discrepancies in regulatory submissions, thus expediting the overall approval timeline. For international companies, this approach is particularly beneficial as it allows them to leverage existing data and documentation prepared for other ICH member countries, thereby optimizing resources and reducing time to market. Embracing these harmonization initiatives can significantly enhance a company’s ability to navigate the regulatory landscape in Korea and ensure compliance with both local and international standards.

Post-Registration Considerations

Getting a drug approved is a significant milestone, but it is not the final step. Ongoing responsibilities follow Korea drug approval.

Pharmacovigilance

Pharmacovigilance is the science of detecting, assessing, and preventing adverse effects or other drug-related problems, crucial for ensuring the safety of pharmaceutical products post-approval. In Korea, international companies must establish a robust pharmacovigilance system in compliance with the Ministry of Food and Drug Safety (MFDS) regulations. This system involves continuous safety monitoring and reporting to identify and mitigate any adverse effects that may arise once the drug is marketed. Effective pharmacovigilance practices help maintain public health and build trust in pharmaceutical products.

Establishing an effective pharmacovigilance system includes creating a comprehensive safety database to track and analyze adverse events. Companies must train their staff in pharmacovigilance practices to ensure they are equipped to handle safety data and report adverse effects accurately and promptly. Developing detailed procedures for the timely and accurate reporting of adverse events is also essential. These procedures should align with MFDS requirements, ensuring that all incidents are documented and reported in a manner that complies with Korean regulations. This proactive approach to pharmacovigilance not only ensures patient safety but also helps international companies maintain regulatory compliance and avoid potential legal and financial repercussions.

Periodic Reporting Requirements

After a drug is approved and on the market in Korea, companies are required to submit regular reports to the Ministry of Food and Drug Safety (MFDS). These periodic reports are essential for providing updates on the drug’s safety, efficacy, and other relevant data gathered during its use in the general population. The continuous assessment of a drug’s risk-benefit profile through these reports is a crucial component of post-marketing surveillance. This ongoing evaluation helps to identify any new adverse effects or changes in the drug’s effectiveness, ensuring that it remains safe and beneficial for patients over time.

To comply with these requirements, companies must be diligent in maintaining detailed records and submitting reports on schedule. Failure to do so can result in significant penalties, including the potential revocation of the drug’s marketing authorization. Ensuring timely and accurate reporting involves having a robust system in place for monitoring the drug’s performance and promptly addressing any issues that arise. Companies should prioritize establishing clear procedures for data collection and reporting, training staff accordingly, and possibly engaging local regulatory experts to navigate the specifics of MFDS regulations effectively. This diligence not only maintains compliance but also supports the overarching goal of safeguarding public health.

Global Innovative Products on Fast Track (GIFT)

At the end of 2022, the Korean Pharma Association conducted an investigation of over 200 drugs approved in Korea between 2011 and 2022. While Japan and Western countries have managed to reduce timelines for new pharmaceutical approvals, Korea experienced a 25% increase in review times over this 10-year period. Additionally, new drug approvals in Korea lagged behind those in Western countries by over 1 year, causing delays for Korean patients that need new drug therapies.

To address delay, Korea launched the Global Innovative Products on Fast Track (GIFT) program at the end of 2022. The Global Innovative Products on Fast Track (GIFT) program aims to speed up the approval of highly innovative drugs in high demand. While it is similar in concept to the FDA’s “Breakthrough Therapy” program, it has unique regulatory details and requirements specific to Korea. The program is designed to help drug companies accelerate their drug approval processes in Korea. As the fourth-largest drug market in Asia with a wealthy population and efforts from the government to supply better and more affordable products, Korea remains an attractive market for drug companies.

The New Approval Process for Vaccines and Orphan Drugs

To expedite the import of vaccines for public health emergencies Korea began reducing the steps required for regulatory approval.

In April 2021, the Ministry of Food and Drug Safety announced measures to simplify the regulatory approval process for vaccines, particularly in public health emergencies, and eliminated the requirement for country-of-origin certificates. This move is part of a new legal framework aimed at accelerating the approval process for orphan drugs used to treat rare diseases. Under the new framework, pharmaceutical manufacturers can, in some cases, submit results from clinical studies conducted outside of Korea instead of starting new Phase III trials in Korea.

The Korean pharmaceutical market is a landscape of immense promise. For international pharmaceutical companies, achieving drug registration in Korea is a rigorous but navigable process. With careful preparation, respect for cultural nuances, and strategic collaborations, foreign entities can effectively enter and thrive in this vibrant market.

Now is an opportune moment for international companies to equip themselves for a seamless entry into Korea’s burgeoning pharmaceutical scene, capitalizing on the robust growth and innovation that characterize this nation’s healthcare industry.

Tran Doan – Director, Pacific Bridge Medical (PBM)
Ms. Doan leads Asian market research, regulatory, and consulting projects at PBM. She graduated with a B.A., Phi Beta Kappa, in Mathematics and Economics from Franklin and Marshall College.

Source used in the article: https://www.mfds.go.kr/eng/wpge/m_17/denofile.do